ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

plecanatide

Also written as “Plecanatide”, “SP-304 0.3 mg” and “SP-304 1.0 mg”.

Its studies are mostly in Constipation · Irritable Bowel Syndrome · Bronchiolitis Obliterans Syndrome, led by 2 companies.

Drug pagePlecanatide: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 6, 201113 company-led studies, 1 open or runningNext primary completion: Oct 18, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companiesits history only121 open or runningphase 3since Sep 6, 2011Jan 12, 2010Oct 18, 2027phase 2 · NCT07723924
Shandong Luoxin Pharmaceutical Group Stock10 open or runningphase 3since Nov 4, 2021Nov 4, 2021none ahead

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Shandong Luoxin Pharmaceutical Group Stock only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 4, 2021First study: phase 3 study in Functional ConstipationFirst studyNCT05151328 · 648 enrolled · China

TargetBeta

GUCY2C →read by rule
“An agonist of intestinal guanylate cyclase type C (GC-C) which is almost structurally identical to human uroguanylin, with laxative and anti-nociceptive activities”NCIt, by rule
“Heat-stable enterotoxin receptor agonist”ChEMBL 37, by rule

Studies

The one study Shandong Luoxin Pharmaceutical Group Stock leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05151328Functional Constipation · China3CompletedOct 12, 2023648

How it is read

Names in the registry

  • “Plecanatide”, 10 entries
  • “plecanatide”, 2 entries
  • “SP-304 0.3 mg”, 1 entry
  • “SP-304 1.0 mg”, 1 entry
  • “SP-304 3.0 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.